PSMA-Targeted Radionuclide Therapy of Metastatic Castration-Resistant Prostate Cancer with ¹⁷⁷Lu-Labeled PSMA-617

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. 1Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinomaOriginal Research · 1998 · 701 citations
2. 2Potent Antitumor Activity of an Auristatin-Conjugated, Fully Human Monoclonal Antibody to Prostate-Specific Membrane AntigenOriginal Research · 2006 · 134 citations
3. 3The role of radiation therapy in the treatment of metastatic castrate-resistant prostate cancerOriginal Research · 2015 · 14 citations
4. 4Phase II Study of Lutetium-177–Labeled Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody J591 for Metastatic Castration-Resistant Prostate CancerCohort Study · 2013 · 427 citations
5. 5Radioimmunotherapy of Prostate Cancer Using 90Y- and 177Lu-Labeled J591 Monoclonal Antibodies: Effect of Multiple Treatments on MyelotoxicityCohort Study · 2005 · 128 citations